---
title: "688266.SH (688266.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688266.SH/news.md"
symbol: "688266.SH"
name: "688266.SH"
parent: "https://longbridge.com/en/quote/688266.SH.md"
datetime: "2026-05-21T03:20:53.308Z"
locales:
  - [en](https://longbridge.com/en/quote/688266.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688266.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688266.SH/news.md)
---

# 688266.SH (688266.SH) — Related News

### [In the first quarterly report, three dark horses emerged in innovative drugs](https://longbridge.com/en/news/286335048.md)
*2026-05-14T00:31:47.000Z*
> The financial performance of innovative pharmaceutical companies in 2026 has become the focus of investors. Hengrui Phar

### [Merck signs local cooperation agreement to continue expanding its innovation cooperation network in China](https://longbridge.com/en/news/286062545.md)
*2026-05-12T08:37:05.000Z*
> Merck Research Laboratories (China) Co., Ltd. has signed a cooperation agreement with Meisai Biotech and Dage Biotech to

### [](https://longbridge.com/en/news/286037190.md)
*2026-05-12T05:05:45.000Z*
> Selective movements in A-share innovative drug stocks: TJPC hit the daily limit in the afternoon, Hengrui Pharma rose ov

### [ZeJing Pharma's Thyroid Cancer Treatment Trial Meets Primary Endpoint](https://longbridge.com/en/news/285514962.md)
*2026-05-07T08:43:55.000Z*
> ZeJing Pharma announced that its injectable human thyrotropin beta has met the primary endpoint in its Phase III clinica

### [Zelgen: The Phase III clinical trial of injectable human thyroid-stimulating hormone has reached the predefined primary endpoint](https://longbridge.com/en/news/285514299.md)
*2026-05-07T08:43:05.000Z*
> Zelgen announced that the Phase III clinical trial of its self-developed injectable human thyroid-stimulating hormone be

### [Zelgen: The controlling shareholder Sheng Zelin and shareholder Ningbo Zeao have respectively reduced their holdings by 0.1035% and 0.935%](https://longbridge.com/en/news/283126926.md)
*2026-04-17T10:14:28.000Z*
> Zelgen announced that its controlling shareholder and actual controller Sheng Zelin reduced his holdings by 273,900 shar